What does SOBEGAPHARMA do?

SOBEGAPHARMA is a pharmacy in Mons. Private Limited, started on 15 May 2008, 1 establishment.

What is the address of SOBEGAPHARMA?

The registered office of SOBEGAPHARMA is located at Rue des Quatre Fils Aymon 2, 7000 Mons.

Is SOBEGAPHARMA still active?

Yes. According to the CBE (2 October 2026) SOBEGAPHARMA is active, legal situation “Normale toestand”, started on 15 May 2008.

Is SOBEGAPHARMA registered on Peppol?

Yes, SOBEGAPHARMA is registered on the Peppol network with ID 0208:0898114684.

What is the enterprise number of SOBEGAPHARMA?

The enterprise number of SOBEGAPHARMA is BE0898114684.

When was SOBEGAPHARMA founded?

SOBEGAPHARMA was founded on 15 May 2008.

Is SOBEGAPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 May 2008; 4 annual accounts filed, latest fiscal year 2025.

How much profit did SOBEGAPHARMA make in 2025?

SOBEGAPHARMA posted a profit after taxes of € 24,247 in financial year 2025.

What is the revenue of SOBEGAPHARMA?

As a small company, SOBEGAPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 183,099.

How many employees does SOBEGAPHARMA have?

According to the 2025 annual accounts, SOBEGAPHARMA has 0.8 full-time equivalents (FTE).

SOBEGAPHARMA (Private Limited) - Mons - BE0898114684

Dossier SOBEGAPHARMA, printed on 2 October 2026 from databakkes.be/en/0898114684/sobegapharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

SOBEGAPHARMA from Mons, company number BE0898114684, closed financial year 2025 with a result of € 24,247 after tax. For that financial year SOBEGAPHARMA recorded a gross margin of € 183,099 and equity of € 187,268. Compared with financial year 2024, the result moved from € 24,196 to € 24,247. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on February 1, 2026.

What it is worth Growing

€ 187,268

▲ 15% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 24,247

Profit after tax over the fiscal year.

Cash in the bank

€ 108,495

▲ 20% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 181,068.

People and assets in 2025

Full-time equivalents

0.8

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 35,368

▲ 8% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 5,673

▼ 49% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 494,475

▼ 14% vs 2024

€ 86,203 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 288,311

▲ 11% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 192,827 Gross margin 2022: € 192,827 First fiscal year in the series	€ 149,783 Gross margin 2023: € 149,783 ▼ 22% vs 2022 (€ 192,827) Unfavourable step	€ 217,585 Gross margin 2024: € 217,585 ▲ 45% vs 2023 (€ 149,783) Favourable step	€ 183,099 Gross margin 2025: € 183,099 ▼ 16% vs 2024 (€ 217,585) Unfavourable step	▼ 16%
Profit after taxes	€ 85,625 Profit after taxes 2022: € 85,625 First fiscal year in the series	€ -13,358 Profit after taxes 2023: € -13,358 ▼ € 98,983 vs 2022 (€ 85,625) Unfavourable step	€ 24,196 Profit after taxes 2024: € 24,196 ▲ € 37,554 vs 2023 (€ -13,358) Favourable step	€ 24,247 Profit after taxes 2025: € 24,247 Unchanged (€ 24,196) Favourable step
Equity	€ 152,183 Equity 2022: € 152,183 First fiscal year in the series	€ 138,825 Equity 2023: € 138,825 ▼ 9% vs 2022 (€ 152,183) Unfavourable step	€ 163,021 Equity 2024: € 163,021 ▲ 17% vs 2023 (€ 138,825) Favourable step	€ 187,268 Equity 2025: € 187,268 ▲ 15% vs 2024 (€ 163,021) Favourable step	▲ 15%
Total debts	€ 795,673 Total debts 2022: € 795,673 First fiscal year in the series	€ 1,042,718 Total debts 2023: € 1,042,718 ▲ 31% vs 2022 (€ 795,673) Unfavourable step	€ 918,080 Total debts 2024: € 918,080 ▼ 12% vs 2023 (€ 1,042,718) Favourable step	€ 848,136 Total debts 2025: € 848,136 ▼ 8% vs 2024 (€ 918,080) Favourable step	▼ 8%
Cash	€ 106,940 Cash 2022: € 106,940 First fiscal year in the series	€ 92,460 Cash 2023: € 92,460 ▼ 14% vs 2022 (€ 106,940) Unfavourable step	€ 90,678 Cash 2024: € 90,678 ▼ 2% vs 2023 (€ 92,460) Unfavourable step	€ 108,495 Cash 2025: € 108,495 ▲ 20% vs 2024 (€ 90,678) Favourable step	▲ 20%
Land & buildings	€ 361,433 Land & buildings 2022: € 361,433 First fiscal year in the series	€ 608,073 Land & buildings 2023: € 608,073 ▲ 68% vs 2022 (€ 361,433) Unchanged	€ 518,611 Land & buildings 2024: € 518,611 ▼ 15% vs 2023 (€ 608,073) Unchanged	€ 429,149 Land & buildings 2025: € 429,149 ▼ 17% vs 2024 (€ 518,611) Unchanged	▼ 17%
Retained profit	€ 145,983 Retained profit 2022: € 145,983 First fiscal year in the series	€ 132,625 Retained profit 2023: € 132,625 ▼ 9% vs 2022 (€ 145,983) Unfavourable step	€ 156,821 Retained profit 2024: € 156,821 ▲ 18% vs 2023 (€ 132,625) Favourable step	€ 181,068 Retained profit 2025: € 181,068 ▲ 15% vs 2024 (€ 156,821) Favourable step	▲ 15%
Bank debt	€ 426,190 Bank debt 2022: € 426,190 First fiscal year in the series	€ 660,072 Bank debt 2023: € 660,072 ▲ 55% vs 2022 (€ 426,190) Unfavourable step	€ 576,922 Bank debt 2024: € 576,922 ▼ 13% vs 2023 (€ 660,072) Favourable step	€ 494,475 Bank debt 2025: € 494,475 ▼ 14% vs 2024 (€ 576,922) Favourable step	▼ 14%
Balance sheet total	€ 947,856 Balance sheet total 2022: € 947,856 First fiscal year in the series	€ 1,181,543 Balance sheet total 2023: € 1,181,543 ▲ 25% vs 2022 (€ 947,856) Unchanged	€ 1,081,101 Balance sheet total 2024: € 1,081,101 ▼ 9% vs 2023 (€ 1,181,543) Unchanged	€ 1,035,404 Balance sheet total 2025: € 1,035,404 ▼ 4% vs 2024 (€ 1,081,101) Unchanged	▼ 4%
Employees (FTE)	0.5 Employees (FTE) 2022: 0.5 First fiscal year in the series	0.6 Employees (FTE) 2023: 0.6 ▲ 0.1 vs 2022 (0.5) Unchanged	0.8 Employees (FTE) 2024: 0.8 ▲ 0.2 vs 2023 (0.6) Unchanged	0.8 Employees (FTE) 2025: 0.8 Unchanged (0.8) Unchanged

Key figures of SOBEGAPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to SOBEGAPHARMA?

What happened at SOBEGAPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Feb 1, 2026 New annual accounts for financial year 2025: profit of € 24,247. filed late Source: NBB ↗
Jun 12, 2008 New establishment in Mons. KBO
May 15, 2008 Start of the company according to the CBE. KBO

In short

From € 85,625 profit in 2022 to € 24,247 profit in 2025.

Paid € 70,164 in corporate taxes since 2022.

Best year ever: 2022, with € 85,625 profit.

Original PDFs at the National Bank ↗

A new publication or filing at SOBEGAPHARMA? We notify you, reason included.

Follow SOBEGAPHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Rue des Quatre Fils Aymon 2

7000 Mons

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Association des Copropriétaires dénommée Angle 4 Fils Aymon/Nimy à Mons, rue des Quatre Fils Aymon, 2, à l'angle de la rue de Nimy

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0898.114.684

VAT number

BE 0898.114.684

Registered office

Rue des Quatre Fils Aymon 2, 7000 Mons

Names & denominations

SOBEGAPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

15 May 2008

Peppol

Active · Active since 30 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Vervaardiging van farmaceutische grondstoffen

Vervaardiging van geneesmiddelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗